How VYNDAMAX® (tafamidis) works

In a clinical trial, VYNDAMAX was proven to significantly reduce death and the number of heart-related hospitalizations in people with ATTR-CM.

Transthyretin (TTR) is an important protein primarily produced in the liver. TTR carries thyroxine (a thyroid hormone) and retinol (vitamin A) throughout the body. TTR is mostly made in the liver but is also made in smaller amounts in the outer lining of the brain and retina.

ATTR-CM occurs when the TTR protein weakens and becomes unstable.

Illustration depicting VYNDAMAX (tafamidis) attaching to the ttr protein. See safety information.

Attach

VYNDAMAX attaches to the TTR protein.

Illustration depicting VYNDAMAX (tafamidis) stabilizing ttr after attaching to the protein. See safety info.

Stabilize

VYNDAMAX stabilizes TTR, helping it stay together.

A heart icon symbolizing VYNDAMAX (tafamidis) stabilizing ttr, slowing the breakdown and buildup of dangerous deposits and slowing the progression of ATTR-CM. See safety info.

Maintain

By stabilizing TTR, VYNDAMAX slows the breakdown and buildup of dangerous deposits, which can help to slow the progression of ATTR-CM.




By slowing the breakdown and buildup of dangerous TTR deposits, VYNDAMAX can help slow the progression of ATTR-CM.